𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The central haemodynamic effects of a single intravenous dose of flosequinan in patients with severe heart failure

✍ Scribed by H. Markus; A. J. Cowley

Publisher
Springer
Year
1991
Tongue
English
Weight
332 KB
Volume
40
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

✦ Synopsis

The acute central haemodynamic and neuroendocrine effects of intravenous flosequinan were studied in a group of 10 patients with severe heart failure. Flosequinan improved cardiac output by a maximum of 1.59 l.min-1, it reduced pulmonary capillary wedge pressure by 11.9 mm Hg and it also caused a reduction in right atrial pressure by a maximum of 7.2 mm Hg. It tended to cause a fall in plasma adrenaline levels but not in plasma noradrenaline. There was little fall in blood pressure in response to flosequinan and no patient developed an adverse event. Intravenous flosequinan may be a useful candidate drug for controlled clinical studies in patients with severe heart failure.

πŸ“œ SIMILAR VOLUMES

Acute haemodynamic and neurohumoral effe
Acute haemodynamic and neurohumoral effects of intravenous nisoldipine in patients with severe congestive heart failure
✍ H. H. Erlemeier; W. Kupper; W. Bleifeld πŸ“‚ Article πŸ“… 1990 πŸ› Springer 🌐 English βš– 473 KB

Twenty patients (5 females, 15 males) with severe heart failure (NYHA IV), due to coronary artery disease in 14, and congestive cardiomyopathy in 6, received an intravenous bolus of the calcium blocker nisoldipine 0.2 mg followed by a continuous infusion of 0.2 micrograms.kg-1.min-1. Haemodynamic me

A comparison of the effects of captopril
A comparison of the effects of captopril and flosequinan in patients with severe heart failure
✍ A. J. Cowley; R. D. Wynne; A. Swami; J. Birkhead; A. Skene; J. R. Hampton πŸ“‚ Article πŸ“… 1992 πŸ› Springer US 🌐 English βš– 542 KB

Angiotensin converting enzyme inhibitors have greatly improved the treatment of patients with chronic heart failure but they are not effective in all patients, and their use may be limited by side effects. There is, therefore, a need to investigate new drugs and to compare their efficacy with angiot